ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

Exclusion Criteria

• •Hormone receptor negative tumours (ER and PR negative)
• •Presence of life-threatening metastatic visceral disease
• •Significant cardiovascular event (e.g. myocardial infarction, superior vena cava \[SVC\] syndrome, New York Heart Association \[NYHA\] classification of heart disease ³2) within 3 months before entry, or presence of cardiac disease that in the opinion of
• •History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG